Adith S. Arun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Adith S. Arun has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Aanavi Karandikar
Personal Genome Diagnostics, Baltimore, Maryland
12 shared publications - Alessandro Leal
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
12 shared publications - Cornelis J A Punt
Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Centre , Utrecht
12 shared publications - Elaine Jiayuee Chiao
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
12 shared publications - Eniko Papp
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
12 shared publications - Gerrit A. Meijer
Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
12 shared publications
Latest Publications
- 1 June 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (6) , e26694
Rising Hypertension Mortality Rates Are Independent of Coding Drift
- 1 June 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (6) , e26694
Rising Hypertension Mortality Rates Are Independent of Coding Drift
- Open Access
- 4 April 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (8) , 1015-1022.e8
Sex differences in all-cause and cause-specific mortality and years of life lost in the United States, 2000-2023
- 4 April 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (8) , 1015-1022.e8
Open AccessSex differences in all-cause and cause-specific mortality and years of life lost in the United States, 2000-2023
- 2 December 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (3) , 896-899
Leading Cause of Death and Life Expectancy Among US Superagers
- 2 December 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (3) , 896-899
Leading Cause of Death and Life Expectancy Among US Superagers
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
Supplementary Data 1 shows an overview of ctDNA dynamics, treatments, and radiological response measurements per patient.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
Supplementary Data 1 shows an overview of ctDNA dynamics, treatments, and radiological response measurements per patient.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
The Supplementary Figures file consists of Supplementary Figures 1 to 15 belonging to the manuscript: "Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells"
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
The Supplementary Figures file consists of Supplementary Figures 1 to 15 belonging to the manuscript: "Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells"
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
The Supplementary Tables file consists of Supplementary Tables 1 to 15 belonging to the manuscript "Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells"
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
The Supplementary Tables file consists of Supplementary Tables 1 to 15 belonging to the manuscript "Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells"
- Open Access
Leading Cause of Death and Life Expectancy Among US Superagers
Importance The United States has the largest gap between lifespan and healthspan, highlighting a need to understand how some older adults maintain good health into advanced age. Objective To describe life expectancy and leading causes of death among US “superagers,” defined as adults aged 80 years and older who report good or excellent health. Design, Setting, and Participants Cross-sectional study of adults aged 80–98 years using 1986–1995 National Health Interview Survey data linked to the National Death Index through 2019. These cohorts were chosen to ensure near-complete mortality follow-up. Exposure Self-reported health status, categorized as superager (excellent/very good/good) or non-superager (fair/poor). Main Outcomes and Measures Weighted mean age at death, cause-specific mortality, and sociodemographic characteristics. Results Among 25,241 participants, 16,491 (65%) were superagers, representing 3.7 million older adults nationally. Superagers lived an average of 2 years longer than their peers (mean age at death 91.6 vs 89.6 years, P <.001). Diseases of the heart were the leading cause of death in both groups (40.7% vs 41.2%). Superagers were more likely to be non-Hispanic White, have at least a high school education, and live alone, but less likely to be Black, Hispanic, or have low education. Conclusions and Relevance US superagers live slightly longer and die from similar causes as peers in poorer health, suggesting their advantage lies in delaying disease onset rather than avoiding it. Persistent racial and educational disparities emphasize the need to expand opportunities for healthy aging across all populations.
Open AccessLeading Cause of Death and Life Expectancy Among US Superagers
Importance The United States has the largest gap between lifespan and healthspan, highlighting a need to understand how some older adults maintain good health into advanced age. Objective To describe life expectancy and leading causes of death among US “superagers,” defined as adults aged 80 years and older who report good or excellent health. Design, Setting, and Participants Cross-sectional study of adults aged 80–98 years using 1986–1995 National Health Interview Survey data linked to the National Death Index through 2019. These cohorts were chosen to ensure near-complete mortality follow-up. Exposure Self-reported health status, categorized as superager (excellent/very good/good) or non-superager (fair/poor). Main Outcomes and Measures Weighted mean age at death, cause-specific mortality, and sociodemographic characteristics. Results Among 25,241 participants, 16,491 (65%) were superagers, representing 3.7 million older adults nationally. Superagers lived an average of 2 years longer than their peers (mean age at death 91.6 vs 89.6 years, P <.001). Diseases of the heart were the leading cause of death in both groups (40.7% vs 41.2%). Superagers were more likely to be non-Hispanic White, have at least a high school education, and live alone, but less likely to be Black, Hispanic, or have low education. Conclusions and Relevance US superagers live slightly longer and die from similar causes as peers in poorer health, suggesting their advantage lies in delaying disease onset rather than avoiding it. Persistent racial and educational disparities emphasize the need to expand opportunities for healthy aging across all populations.
- 16 April 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
Reevaluating the Threshold for Low Total Testosterone
- 16 April 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
Reevaluating the Threshold for Low Total Testosterone
- Open Access
- 15 April 2024
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 10 (4) , 101506
Endovascular stenting of external iliac vein injury during anterior spine exposure
- 15 April 2024
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 10 (4) , 101506
Open AccessEndovascular stenting of external iliac vein injury during anterior spine exposure
- Open Access
Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization
Introduction: A chronic post-vaccination syndrome (PVS) after covid-19 vaccination has been reported but has yet to be well characterized. Methods: We included 241 individuals aged 18 and older who self-reported PVS after covid-19 vaccination and who joined the online Yale Listen to Immune, Symptom and Treatment Experiences Now (LISTEN) Study from May 2022 to July 2023. We summarized their demographics, health status, symptoms, treatments tried, and overall experience. Results: The median age of participants was 46 years (interquartile range [IQR]: 38 to 56), with 192 (80%) identifying as female, 209 (87%) as non-Hispanic White, and 211 (88%) from the United States. Among these participants with PVS, 127 (55%) had received the BNT162b2 [Pfizer-BioNTech] vaccine, and 86 (37%) received the mRNA-1273 [Moderna] vaccine. The median time from the day of index vaccination to symptom onset was three days (IQR: 1 day to 8 days). The time from vaccination to symptom survey completion was 595 days (IQR: 417 to 661 days). The median Euro-QoL visual analogue scale score was 50 (IQR: 39 to 70). The five most common symptoms were exercise intolerance (71%), excessive fatigue (69%), numbness (63%), brain fog (63%), and neuropathy (63%). In the week before survey completion, participants reported feeling unease (93%), fearfulness (82%), and overwhelmed by worries (81%), as well as feelings of helplessness (80%), anxiety (76%), depression (76%), hopelessness (72%), and worthlessness (49%) at least once. Participants reported a median of 20 (IQR: 13 to 30) interventions to treat their condition. Conclusions: In this study, individuals who reported PVS after covid-19 vaccination had low health status, high symptom burden, and high psychosocial stress despite trying many treatments. There is a need for continued investigation to understand and treat this condition.
Open AccessPost-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization
Introduction: A chronic post-vaccination syndrome (PVS) after covid-19 vaccination has been reported but has yet to be well characterized. Methods: We included 241 individuals aged 18 and older who self-reported PVS after covid-19 vaccination and who joined the online Yale Listen to Immune, Symptom and Treatment Experiences Now (LISTEN) Study from May 2022 to July 2023. We summarized their demographics, health status, symptoms, treatments tried, and overall experience. Results: The median age of participants was 46 years (interquartile range [IQR]: 38 to 56), with 192 (80%) identifying as female, 209 (87%) as non-Hispanic White, and 211 (88%) from the United States. Among these participants with PVS, 127 (55%) had received the BNT162b2 [Pfizer-BioNTech] vaccine, and 86 (37%) received the mRNA-1273 [Moderna] vaccine. The median time from the day of index vaccination to symptom onset was three days (IQR: 1 day to 8 days). The time from vaccination to symptom survey completion was 595 days (IQR: 417 to 661 days). The median Euro-QoL visual analogue scale score was 50 (IQR: 39 to 70). The five most common symptoms were exercise intolerance (71%), excessive fatigue (69%), numbness (63%), brain fog (63%), and neuropathy (63%). In the week before survey completion, participants reported feeling unease (93%), fearfulness (82%), and overwhelmed by worries (81%), as well as feelings of helplessness (80%), anxiety (76%), depression (76%), hopelessness (72%), and worthlessness (49%) at least once. Participants reported a median of 20 (IQR: 13 to 30) interventions to treat their condition. Conclusions: In this study, individuals who reported PVS after covid-19 vaccination had low health status, high symptom burden, and high psychosocial stress despite trying many treatments. There is a need for continued investigation to understand and treat this condition.